Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia

Differentiation

Volumn 82, Issue 4-5, 2011, Pages 261-271

  Wang, Zongwei ^a,b   Olumi, Aria F ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Benign prostatic hyperplasia; C Jun; Diabetes; Hyperinsulinaemia; Insulin like growth factor; Insulin like growth factor binding protein

Indexed keywords

ANDROSTANEDIOL; GONADORELIN ANTAGONIST; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN C JUN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TESTOSTERONE;

ADRENERGIC SYSTEM; CASTRATION; CELL INTERACTION; CELL PROLIFERATION; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REVIEW; STROMA CELL;

DIABETES MELLITUS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; SOMATOMEDINS; TRANSCRIPTIONAL ACTIVATION;

EID: 80052967098     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2011.04.004     Document Type: Review

References (147)

1. Abbas A., Grant P.J., Kearney M.T. Role of IGF-I in glucose regulation and cardiovascular disease. Expert. Rev. Cardiovasc. Ther. 2008, 6:1135-1149.
2. Amiel S.A., Sherwin R.S., Hintz R.L., Gertner J.M., Press C.M., Tamborlane W.V. Effect of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes. Diabetes 1984, 33:1175-1179.
3. Angel P., Szabowski A. Function of AP-1 target genes in mesenchymal-epithelial cross-talk in skin. Biochem. Pharmacol. 2002, 64:949-956.
4. Angel P., Szabowski A., Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 2001, 20:2413-2423.
5. Anim J.T., Udo C., John B. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta. Histochem. 1998, 100:439-449.
6. Asplin C.M., Faria A.C., Carlsen E.C., Vaccaro V.A., Barr R.E., Iranmanesh A., Lee M.M., Veldhuis J.D., Evans W.S. Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1989, 69:239-245.
7. Baker J., Liu J.P., Robertson E.J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75:73-82.
8. Barni T., Vannelli B.G., Sadri R., Pupilli C., Ghiandi P., Rizzo M., Selli C., Serio M., Fiorelli G. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: Gene expression and its cellular localization. J. Clin. Endocrinol. Metab. 1994, 78:778-783.
9. Baxter R.C. Insulin-like growth factor (IGF)-binding proteins: Interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. Endocrinol. Metab. 2000, 278:E967-976.
10. Boni-Schnetzler M., Schmid C., Meier P.J., Froesch E.R. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am. J. Physiol. 1991, 260:E846-851.
11. Bonnet P., Reiter E., Bruyninx M., Sente B., Dombrowicz D., de Leval J., Closset J., Hennen G. Benign prostatic hyperplasia and normal prostate aging: Differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels. J. Clin. Endocrinol. Metab. 1993, 77:1203-1208.
12. Boudon C., Rodier G., Lechevallier E., Mottet N., Barenton B., Sultan C Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J. Clin. Endocrinol. Metab. 1996, 81:612-617.
13. Boulware S.D., Tamborlane W.V., Rennert N.J., Gesundheit N., Sherwin R.S Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J. Clin. Invest. 1994, 93:1131-1139.
14. Bourke J.B., Griffin J.P. Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br. J. Urol. 1966, 38:18-23.
15. Bradham C., McClay D.R. p38 MAPK in development and cancer. Cell Cycle 2006, 5:824-828.
16. Bramnert M., Segerlantz M., Laurila E., Daugaard J.R., Manhem P., Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J. Clin. Endocrinol. Metab. 2003, 88:1455-1463.
17. Brown J.S., Wessells H., Chancellor M.B., Howards S.S., Stamm W.E., Stapleton A.E., Steers W.D., Van Den Eeden S.K., McVary K.T. Urologic complications of diabetes. Diabetes Care 2005, 28:177-185.
18. Burke J.P., Jacobson D.J., McGree M.E., Roberts R.O., Girman C.J., Lieber M.M., Jacobsen S.J. Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota. Urology 2006, 67:22-25.
19. Butler A.A., Le Roith D. Control of growth by the somatropic axis: Growth hormone and the insulin-like growth factors have related and independent roles. Annu. Rev. Physiol. 2001, 63:141-164.
20. Carmena M.J., Fernandez-Moreno M.D., Prieto J.C. Characterization of insulin receptors in isolated epithelial cells of rat ventral prostate: Effect of fasting. Cell. Biochem. Funct. 1986, 4:19-24.
21. Carroll P.V., Umpleby M., Alexander E.L., Egel V.A., Callison K.V., Sonksen P.H., Russell-Jones D.L. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: Effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clin. Endocrinol. (Oxf) 1998, 49:739-746.
22. Cheetham T.D., Holly J.M., Clayton K., Cwyfan-Hughes S., Dunger D.B. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type 1 diabetes. Diabet. Med. 1995, 12:885-892.
23. Chokkalingam A.P., Gao Y.T., Deng J., Stanczyk F.Z., Sesterhenn I.A., Mostofi F.K., Fraumeni J.F., Hsing A.W. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002, 52:98-105.
24. Clemmons D.R., Maile L.A. Interaction between insulin-like growth factor-I receptor and alphaVbeta3 integrin linked signaling pathways: Cellular responses to changes in multiple signaling inputs. Mol. Endocrinol. 2005, 19:1-11.
25. Cohen P., Peehl D.M., Baker B., Liu F., Hintz R.L., Rosenfeld R.G. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 1994, 79:1410-1415.
26. Cohen P., Peehl D.M., Lamson G., Rosenfeld R.G. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. 1991, 73:401-407.
27. Colao A., Marzullo P., Spiezia S., Ferone D., Giaccio A., Cerbone G., Pivonello R., Di Somma C., Lombardi G. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: An ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J. Clin. Endocrinol. Metab. 1999, 84:1986-1991.
28. Colao A., Spiezia S., Di Somma C., Marzullo P., Cerbone G., Pivonello R., Faggiano A., Lombardi G. Effect of GH and/or testosterone deficiency on the prostate: An ultrasonographic and endocrine study in GH-deficient adult patients. Eur. J. Endocrinol. 2000, 143:61-69.
29. Cowie C.C., Rust K.F., Byrd-Holt D.D., Eberhardt M.S., Flegal K.M., Engelgau M.M., Saydah S.H., Williams D.E., Geiss L.S., Gregg E.W. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006, 29:1263-1268.
30. Cowie C.C., Rust K.F., Byrd-Holt D.D., Gregg E.W., Ford E.S., Geiss L.S., Bainbridge K.E., Fradkin J.E. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010, 33:562-568.
31. Cunha G.R. Stromal induction and specification of morphogenesis and cytodifferentiation of the epithelia of the Mullerian ducts and urogenital sinus during development of the uterus and vagina in mice. J. Exp. Zool. 1976, 196:361-370.
32. Cunha G.R., Chung L.W. Stromal-epithelial interactions--I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J. Steroid Biochem. 1981, 14:1317-1324.
33. Dahle S.E., Chokkalingam A.P., Gao Y.T., Deng J., Stanczyk F.Z., Hsing A.W. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol 2002, 168:599-604.
34. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
35. Dong G., Rajah R., Vu T., Hoffman A.R., Rosenfeld R.G., Roberts C.T., Peehl D.M., Cohen P. Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 1997, 82:2198-2203.
36. Eferl R., Wagner E.F. AP-1: A double-edged sword in tumorigenesis. Nat. Rev. Cancer 2003, 3:859-868.
37. Federici M., Giaccari A., Hribal M.L., Giovannone B., Lauro D., Morviducci L., Pastore L., Tamburrano G., Lauro R., Sesti G. Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly. Diabetes 1999, 48:2277-2285.
38. Federici M., Lauro D., D'Adamo M., Giovannone B., Porzio O., Mellozzi M., Tamburrano G., Sbraccia P., Sesti G. Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia. Diabetes 1998, 47:87-92.
39. Federici M., Zucaro L., Porzio O., Massoud R., Borboni P., Lauro D., Sesti G. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects. J. Clin. Invest. 1996, 98:2887-2893.
40. Fiorelli G., De Bellis A., Longo A., Giannini S., Natali A., Costantini A., Vannelli G.B., Serio M. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: Characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J. Clin. Endocrinol. Metab. 1991, 72:740-746.
41. Fryburg D.A., Jahn L.A., Hill S.A., Oliveras D.M., Barrett E.J. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J. Clin. Invest. 1995, 96:1722-1729.
42. Frystyk J. Exercise and the growth hormone-insulin-like growth factor axis. Med. Sci. Sports Exerc. 2010, 42:58-66.
43. Frystyk J., Grofte T., Skjaerbaek C., Orskov H. The effect of oral glucose on serum free insulin-like growth factor-I and -II in health adults. J. Clin. Endocrinol. Metab. 1997, 82:3124-3127.
44. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
45. Gibson J.M., Westwood M., Young R.J., White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J. Clin. Endocrinol. Metab. 1996, 81:860-863.
46. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm. Metab. Res. 2003, 35:694-704.
47. Grant E.S., Ross M.B., Ballard S., Naylor A., Habib F.K. The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells. J. Clin. Endocrinol. Metab. 1998, 83:3252-3257.
48. Guler H.P., Zapf J., Froesch E.R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N. Engl. J. Med. 1987, 317:137-140.
49. Gupta A., Gupta S., Pavuk M., Roehrborn C.G. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: A prospective cohort study of Air Force veterans. Urology 2006, 68:1198-1205.
50. Haffner S., Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003, 108:1541-1545.
51. Haffner S.M. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: Epidemiological and clinical correlation. Int. J. Obes. Relat. Metab. Disord. 2000, 24(Suppl 2):S56-58.
52. Hald T. Urodynamics in benign prostatic hyperplasia: A survey. Prostate Suppl. 1989, 2:69-77.
53. Hammarsten J., Damber J.E., Karlsson M., Knutson T., Ljunggren O., Ohlsson C., Peeker R., Smith U., Mellstrom D. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2009, 12:160-165.
54. Hammarsten J., Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999, 8:29-36.
55. Hammarsten J., Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 2001, 39:151-158.
56. Hammarsten J., Hogstedt B., Holthuis N., Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998, 1:157-162.
57. Hansen A.P., Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 1970, 6:27-33.
58. Hautanen A. Synthesis and regulation of sex hormone-binding globulin in obesity. Int. J. Obes. Relat. Metab. Disord. 2000, 24(Suppl 2):S64-70.
59. Heald A.H., Cruickshank J.K., Riste L.K., Cade J.E., Anderson S., Greenhalgh A., Sampayo J., Taylor W., Fraser W., White A., Gibson J.M. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001, 44:333-339.
60. Issa M.M., Regan T.S. Medical therapy for benign prostatic hyperplasia-present and future impact. Am. J. Manag. Care 2007, 13(Suppl 1):S4-S9.
61. Janssen J.A., Stolk R.P., Pols H.A., Grobbee D.E., Lamberts S.W Serum free and total insulin-like growth factor-I, insulin-like growth factor binding protein-1 and insulin-like growth factor binding protein-3 Levels in healthy elderly individuals. Relation to self-reported quality of health and disability. Gerontology 1998, 44:277-280.
62. Jerde, T.J., Bushman, W., 2009 IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia. Sci. Signal. 2:ra49.
63. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: Biological actions. Endocr. Rev. 1995, 16:3-34.
64. Katz L.E., DeLeon D.D., Zhao H., Jawad A.F. Free and total insulin-like growth factor (IGF)-I levels decline during fasting: Relationships with insulin and IGF-binding protein-1. J. Clin. Endocrinol. Metab. 2002, 87:2978-2983.
65. Kirby M.G., Wagg A., Cardozo L., Chapple C., Castro-Diaz D., de Ridder D., Espuna-Pons M., Haab F., Kelleher C., Kolbl H., Milsom I., Van Kerrebroeck P., Vierhout M., Salvatore S., Tubaro A. Overactive bladder: Is there a link to the metabolic syndrome in men?. Neurourol Urodyn. 2010, 29:1360-1364.
66. Kleinberg D.L., Ruan W., Yee D., Kovacs K.T., Vidal S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. Endocrinology 2007, 148:1080-1088.
67. Krag M.B., Gormsen L.C., Guo Z., Christiansen J.S., Jensen M.D., Nielsen S., Jorgensen J.O. Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E920-927.
68. Laager R., Ninnis R., Keller U Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J. Clin. Invest. 1993, 92:1903-1909.
69. Landsberg L. Diet, obesity and hypertension: An hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q. J. Med. 1986, 61:1081-1090.
70. Lang C.H., Vary T.C., Frost R.A. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology 2003, 144:3922-3933.
71. Larue L., Bellacosa A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24:7443-7454.
72. LeRoith D., Baserga R., Helman L., Roberts C.T. Insulin-like growth factors and cancer. Ann. Intern. Med. 1995, 122:54-59.
73. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995, 16:143-163.
74. Lewitt M.S., Denyer G.S., Cooney G.J., Baxter R.C. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 1991, 129:2254-2256.
75. Lewitt M.S., Hilding A., Brismar K., Efendic S., Ostenson C.G., Hall K. IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. Eur. J. Endocrinol. 2010, 163:233-242.
76. Li W., Wu C.L., Febbo P.G., Olumi A.F. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am. J. Pathol. 2007, 171:1189-1198.
77. Luo J., Dunn T., Ewing C., Sauvageot J., Chen Y., Trent J., Isaacs W. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 2002, 51:189-200.
78. MacCorkle R.A., Tan T.H. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem. Biophys. 2005, 43:451-461.
79. Modric T., Silha J.V., Shi Z., Gui Y., Suwanichkul A., Durham S.K., Powell D.R., Murphy L.J. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology 2001, 142:1958-1967.
80. Mohan S., Baylink D.J. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J. Endocrinol. 2002, 175:19-31.
81. Moller N., Butler P.C., Antsiferov M.A., Alberti K.G. Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia 1989, 32:105-110.
82. Moller N., Jorgensen J.O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 2009, 30:152-177.
83. Moller N., Schmitz O., Joorgensen J.O., Astrup J., Bak J.F., Christensen S.E., Alberti K.G., Weeke J. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J. Clin. Endocrinol. Metab. 1992, 74:1012-1019.
84. Monti S., Di Silverio F., Iraci R., Martini C., Lanzara S., Falasca P., Poggi M., Stigliano A., Sciarra F., Toscano V. Regional ariations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. J. Clin. Endocrinol. Metab. 2001, 86:1700-1706.
85. Monti S., Di Silverio F., Lanzara S., Varasano P., Martini C., Tosti-Croce C., Sciarra F. Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: Relationship with binding proteins 2 and 3 and androgens. Steroids 1998, 63:362-366.
86. Morgan D.A., Balon T.W., Ginsberg B.H., Mark A.L. Nonuniform regional sympathetic nerve responses to hyperinsulinemia in rats. Am. J. Physiol. 1993, 264:R423-427.
87. Morrow L.A., O'Brien M.B., Moller D.E., Flier J.S., Moses A.C. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J. Clin. Endocrinol. Metab 1994, 79:205-210.
88. Moses A.C., Young S.C., Morrow L.A., O'Brien M., Clemmons D.R. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996, 45:91-100.
89. Nandeesha H., Koner B.C., Dorairajan L.N., Sen S.K. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin. Chim. Acta 2006, 370:89-93.
90. Nemet D., Eliakim A. Growth hormone-insulin-like growth factor-1 and inflammatory response to a single exercise bout in children and adolescents. Med. Sport. Sci. 2010, 55:141-155.
91. Neuhouser M.L., Schenk J., Song Y.J., Tangen C.M., Goodman P.J., Pollak M., Penson D.F., Thompson I.M., Kristal A.R. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 2008, 68:1477-1486.
92. Nickel J.C., Downey J., Young I., Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999, 84:976-981.
93. Nickerson T., Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology 1999, 54:1120-1125.
94. Nielsen S., Moller N., Christiansen J.S., Jorgensen J.O. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 2001, 50:2301-2308.
95. Nissley P., Lopaczynski W. Insulin-like growth factor receptors. Growth Factors 1991, 5:29-43.
96. Nyomba B.L., Berard L., Murphy L.J. Free insulin-like growth factor I (IGF-I) in healthy subjects: Relationship with IGF-binding proteins and insulin sensitivity. J. Clin. Endocrinol. Metab. 1997, 82:2177-2181.
97. Ohlson N., Bergh A., Nygren K., Stattin P., Wikstrom P. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome. Eur. Urol. 2006, 49:675-683.
98. Ohlson N., Bergh A., Stattin P., Wikstrom P. Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-I levels. Prostate 2007, 67:32-40.
99. Ozden, C., Ozdal, O.L., Urgancioglu, G., Koyuncu, H., Gokkaya, S., Memis, A., 2007 The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur. Urol. 51, 199-203; discussion 204-196.
100. Papatsoris A.G., Papavassiliou A.G. Molecular 'palpation' of BPH: A tale of MAPK signalling?. Trends Mol. Med. 2001, 7:288-292.
101. Parsons J.K., Bergstrom J., Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2008, 101:313-318.
102. Parsons J.K., Carter H.B., Partin A.W., Windham B.G., Metter E.J., Ferrucci L., Landis P., Platz E.A. Metabolic factors associated with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 2006, 91:2562-2568.
103. Peehl D.M., Cohen P., Rosenfeld R.G. The insulin-like growth factor system in the prostate. World J. Urol. 1995, 13:306-311.
104. Peehl D.M., Cohen P., Rosenfeld R.G. The role of insulin-like growth factors in prostate biology. J. Androl. 1996, 17:2-4.
105. Pertseva M.N., Shpakov A.O., Plesneva S.A., Kuznetsova L.A. A novel view on the mechanisms of action of insulin and other insulin superfamily peptides: Involvement of adenylyl cyclase signaling system. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2003, 134:11-36.
106. Piatti P.M., Monti L.D., Caumo A., Conti M., Magni F., Galli-Kienle M., Fochesato E., Pizzini A., Baldi L., Valsecchi G., Pontiroli A.E. Mediation of the hepatic effects of growth hormone by its lipolytic activity. J. Clin. Endocrinol. Metab. 1999, 84:1658-1663.
107. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
108. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4:505-518.
109. Pratipanawatr T., Pratipanawatr W., Rosen C., Berria R., Bajaj M., Cusi K., Mandarino L., Kashyap S., Belfort R., DeFronzo R.A. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E1360-1368.
110. Rajpathak S.N., Gunter M.J., Wylie-Rosett J., Ho G.Y., Kaplan R.C., Muzumdar R., Rohan T.E., Strickler H.D. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab. Res. Rev. 2009, 25:3-12.
111. Rajpathak S.N., McGinn A.P., Strickler H.D., Rohan T.E., Pollak M., Cappola A.R., Kuller L., Xue X., Newman A.B., Strotmeyer E.S., Psaty B.M., Kaplan R.C. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm. IGF Res. 2008, 18:166-173.
112. Regan F.M., Williams R.M., McDonald A., Umpleby A.M., Acerini C.L., O'Rahilly S., Hovorka R., Semple R.K., Dunger D.B. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. J. Clin. Endocrinol. Metab. 2010, 95:2113-2122.
113. Reinehr T., Kleber M., Toschke A.M., Woelfle J., Roth C.L. Longitudinal association between IGFBP-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss. Int. J. Pediatr. Obes 2011.
114. Rick F.G., Schally A.V., Block N.L., Nadji M., Szepeshazi K., Zarandi M., Vidaurre I., Perez R., Halmos G., Szalontay L. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc. Natl. Acad. Sci. USA 2011, 108:3755-3760.
115. Roberts R.O., Jacobson D.J., Girman C.J., Rhodes T., Klee G.G., Lieber M.M., Jacobsen S.J. Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. Am. J. Epidemiol. 2003, 157:784-791.
116. Rosenbloom A.L. Mecasermin (recombinant human insulin-like growth factor I). Adv. Ther. 2009, 26:40-54.
117. Roy R.N., Cecutti A., Gerulath A.H., Steinberg W.M., Bhavnani B.R. Endometrial transcripts of human insulin-like growth factors arise by differential promoter usage. Mol. Cell. Endocrinol. 1997, 135:11-19.
118. Ruan W., Powell-Braxton L., Kopchick J.J., Kleinberg D.L. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 1999, 140:1984-1989.
119. Russell-Jones D.L., Bates A.T., Umpleby A.M., Hennessy T.R., Bowes S.B., Hopkins K.D., Jackson N., Kelly J., Shojaee-Moradie F., Jones R.H., et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur. J. Clin. Invest. 1995, 25:403-411.
120. Russell-Jones D.L., Rattray M., Wilson V.J., Jones R.H., Sonksen P.H., Thomas C.R. Intraperitoneal insulin is more potent than subcutaneous insulin at restoring hepatic insulin-like growth factor-I mRNA levels in the diabetic rat: A functional role for the portal vascular link. J. Mol. Endocrinol. 1992, 9:257-263.
121. Sarma A.V., Burke J.P., Jacobson D.J., McGree M.E., Sauver J., Girman C.J., Lieber M.M., Herman W., Macoska J., Montie J.E., Jacobsen S.J. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care 2008, 31:476-482.
122. Saukkonen T., Amin R., Williams R.M., Fox C., Yuen K.C., White M.A., Umpleby A.M., Acerini C.L., Dunger D.B. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J. Clin. Endocrinol. Metab. 2004, 89:4634-4641.
123. Saukkonen T., Shojaee-Moradie F., Williams R.M., Amin R., Yuen K.C., Watts A., Acerini C.L., Umpleby A.M., Dunger D.B. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 2006, 55:2365-2370.
124. Schedlich L.J., Le Page S.L., Firth S.M., Briggs L.J., Jans D.A., Baxter R.C. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J. Biol. Chem. 2000, 275:23462-23470.
125. Schmid C., Bianda T., Zwimpfer C., Zapf J., Wiesli P. Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels. Growth Horm. IGF Res. 2005, 15:300-303.
126. Sesti G., Sciacqua A., Cardellini M., Marini M.A., Maio R., Vatrano M., Succurro E., Lauro R., Federici M., Perticone F., Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 2005, 28:120-125.
127. Shpakov A.O., Plesneva S.A., Kuznetsova L.A., Pertseva M.N. Study of the functional organization of a novel adenylate cyclase signaling mechanism of insulin action. Biochemistry (Mosc) 2002, 67:335-342.
128. Silha J.V., Gui Y., Mishra S., Leckstrom A., Cohen P., Murphy L.J. Overexpression of gly56/gly80/gly81-mutant insulin-like growth factor-binding protein-3 in transgenic mice. Endocrinology 2005, 146:1523-1531.
129. Singer C., Rasmussen A., Smith H.S., Lippman M.E., Lynch H.T., Cullen K.J. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: Evidence for paracrine function. Cancer Res. 1995, 55:2448-2454.
130. Smith, R.G., Pong, S.S., Hickey, G., Jacks, T., Cheng, K., Leonard, R., Cohen, C.J., Arena, J.P., Chang, C.H., Drisko, J., Wyvratt, M., Fisher, M., Nargund, R., Patchett, A., 1996. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent. Prog. Horm. Res. 51, 261-285.
131. Soldin O.P., Dahlin J.R., Gresham E.G., King J., Soldin S.J. IMMULITE 2000 age and sex-specific reference intervals for alpha fetoprotein, homocysteine, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, C-peptide, immunoglobulin E and intact parathyroid hormone. Clin. Biochem. 2008, 41:937-942.
132. Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 2005, 9:59-71.
133. Stattin P., Kaaks R., Riboli E., Ferrari P., Dechaud H., Hallmans G. Circulating insulin-like growth factor-I and benign prostatic hyperplasia-A prospective study. Scand. J. Urol. Nephrol. 2001, 35:122-126.
134. Szabowski A., Maas-Szabowski N., Andrecht S., Kolbus A., Schorpp-Kistner M., Fusenig N.E., Angel P. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 2000, 103:745-755.
135. Thomson A.A., Foster B.A., Cunha G.R. Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development 1997, 124:2431-2439.
136. Torring N., Vinter-Jensen L., Pedersen S.B., Sorensen F.B., Flyvbjerg A., Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J. Urol. 1997, 158:222-227.
137. Vendola K., Zhou J., Wang J., Bondy C.A. Androgens promote insulin-like growth factor-I and insulin-like growth factor-I receptor gene expression in the primate ovary. Hum. Reprod. 1999, 14:2328-2332.
138. Wagner E.F. AP-1--Introductory remarks. Oncogene 2001, 20:2334-2335.
139. Wu Y., Zhao W., Zhao J., Pan J., Wu Q., Zhang Y., Bauman W.A., Cardozo C.P. Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology 2007, 148:2984-2993.
140. Wurzburger M.I., Prelevic G.M., Sonksen P.H., Balint-Peric L.A., Wheeler M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J. Clin. Endocrinol. Metab. 1993, 77:267-272.
141. Yamanaka Y., Fowlkes J.L., Wilson E.M., Rosenfeld R.G., Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: Kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 1999, 140:1319-1328.
142. Yu S., Zhang C., Lin C.C., Niu Y., Lai K.P., Chang H.C., Yeh S.D., Chang C., Yeh S. Altered prostate epithelial development and IGF-I signal in mice lacking the androgen receptor in stromal smooth muscle cells. Prostate 2011, 71:7.
143. Zapf J., Hauri C., Waldvogel M., Froesch E.R. Acute metabolic effects and half-lives of intravenously administered insulin like growth factors I and II in normal and hypophysectomized rats. J. Clin. Invest. 1986, 77:1768-1775.
144. Zenobi P.D., Glatz Y., Keller A., Graf S., Jaeggi-Groisman S.E., Riesen W.F., Schoenle E.J., Froesch E.R. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur. J. Endocrinol. 1994, 131:251-257.
145. Zenobi P.D., Graf S., Ursprung H., Froesch E.R. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J. Clin. Invest. 1992, 89:1908-1913.
146. Zenobi P.D., Jaeggi-Groisman S.E., Riesen W.F., Roder M.E., Froesch E.R. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J. Clin. Invest. 1992, 90:2234-2241.
147. Zhang D., Bar-Eli M., Meloche S., Brodt P. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: The phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J. Biol. Chem. 2004, 279:19683-19690.